This posit is coming to reality with the 2022 FDA approval of Enhertu (fam‐trastuzumab‐deruxtecan‐nxki), the first treatment for unresectable or metastatic HER2‐low breast cancer.14 The gene discussed is ERBB2; the disease is breast carcinoma.